Targeting GSK-3

A promising approach for cancer therapy?

Andrei V. Ougolkov, Daniel D Billadeau

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Glycogen synthase kinase (GSK)-3 has emerged as one of the most attractive therapeutic targets for the treatment of multiple neurological diseases, including Alzheimer's, stroke and bipolar disorders, as well as noninsulin-dependent diabetes mellitus and inflammation. Although the prominent role of GSK-3 in the adenomatous polyposis coli (APC)-β-catenin destruction complex implies that inhibition of GSK-3 could possibly lead to tumor promotion through the activation of β-catenin, several recent studies have shed new light on the activity of GSK-3 in cancer and provide insight into the molecular mechanisms by which it regulates tumor cell proliferation and survival of multiple human malignancies. In fact, GSK-3β is a critical regulator of nuclear factor (NF)κB nuclear activity, suggesting that inhibition of GSK-3β could be effective in the treatment of a wide variety of tumors with constitutively active NFκB. Herein, the authors will discuss the current understanding of the role of GSK-3 in human cancer and its potential as a therapeutic target.

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalFuture Oncology
Volume2
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

Glycogen Synthase Kinase 3
Neoplasms
Catenins
Therapeutics
Adenomatous Polyposis Coli
Bipolar Disorder
Type 2 Diabetes Mellitus
Cell Survival
Alzheimer Disease
Stroke
Cell Proliferation
Inflammation

Keywords

  • Cancer
  • Glycogen synthase kinase (GSK)-3
  • Nuclear factor (NF)κB

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting GSK-3 : A promising approach for cancer therapy? / Ougolkov, Andrei V.; Billadeau, Daniel D.

In: Future Oncology, Vol. 2, No. 1, 02.2006, p. 91-100.

Research output: Contribution to journalArticle

Ougolkov, Andrei V. ; Billadeau, Daniel D. / Targeting GSK-3 : A promising approach for cancer therapy?. In: Future Oncology. 2006 ; Vol. 2, No. 1. pp. 91-100.
@article{c16282b419cd4712b2f235e26b4bfc5b,
title = "Targeting GSK-3: A promising approach for cancer therapy?",
abstract = "Glycogen synthase kinase (GSK)-3 has emerged as one of the most attractive therapeutic targets for the treatment of multiple neurological diseases, including Alzheimer's, stroke and bipolar disorders, as well as noninsulin-dependent diabetes mellitus and inflammation. Although the prominent role of GSK-3 in the adenomatous polyposis coli (APC)-β-catenin destruction complex implies that inhibition of GSK-3 could possibly lead to tumor promotion through the activation of β-catenin, several recent studies have shed new light on the activity of GSK-3 in cancer and provide insight into the molecular mechanisms by which it regulates tumor cell proliferation and survival of multiple human malignancies. In fact, GSK-3β is a critical regulator of nuclear factor (NF)κB nuclear activity, suggesting that inhibition of GSK-3β could be effective in the treatment of a wide variety of tumors with constitutively active NFκB. Herein, the authors will discuss the current understanding of the role of GSK-3 in human cancer and its potential as a therapeutic target.",
keywords = "Cancer, Glycogen synthase kinase (GSK)-3, Nuclear factor (NF)κB",
author = "Ougolkov, {Andrei V.} and Billadeau, {Daniel D}",
year = "2006",
month = "2",
doi = "10.2217/14796694.2.1.91",
language = "English (US)",
volume = "2",
pages = "91--100",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Targeting GSK-3

T2 - A promising approach for cancer therapy?

AU - Ougolkov, Andrei V.

AU - Billadeau, Daniel D

PY - 2006/2

Y1 - 2006/2

N2 - Glycogen synthase kinase (GSK)-3 has emerged as one of the most attractive therapeutic targets for the treatment of multiple neurological diseases, including Alzheimer's, stroke and bipolar disorders, as well as noninsulin-dependent diabetes mellitus and inflammation. Although the prominent role of GSK-3 in the adenomatous polyposis coli (APC)-β-catenin destruction complex implies that inhibition of GSK-3 could possibly lead to tumor promotion through the activation of β-catenin, several recent studies have shed new light on the activity of GSK-3 in cancer and provide insight into the molecular mechanisms by which it regulates tumor cell proliferation and survival of multiple human malignancies. In fact, GSK-3β is a critical regulator of nuclear factor (NF)κB nuclear activity, suggesting that inhibition of GSK-3β could be effective in the treatment of a wide variety of tumors with constitutively active NFκB. Herein, the authors will discuss the current understanding of the role of GSK-3 in human cancer and its potential as a therapeutic target.

AB - Glycogen synthase kinase (GSK)-3 has emerged as one of the most attractive therapeutic targets for the treatment of multiple neurological diseases, including Alzheimer's, stroke and bipolar disorders, as well as noninsulin-dependent diabetes mellitus and inflammation. Although the prominent role of GSK-3 in the adenomatous polyposis coli (APC)-β-catenin destruction complex implies that inhibition of GSK-3 could possibly lead to tumor promotion through the activation of β-catenin, several recent studies have shed new light on the activity of GSK-3 in cancer and provide insight into the molecular mechanisms by which it regulates tumor cell proliferation and survival of multiple human malignancies. In fact, GSK-3β is a critical regulator of nuclear factor (NF)κB nuclear activity, suggesting that inhibition of GSK-3β could be effective in the treatment of a wide variety of tumors with constitutively active NFκB. Herein, the authors will discuss the current understanding of the role of GSK-3 in human cancer and its potential as a therapeutic target.

KW - Cancer

KW - Glycogen synthase kinase (GSK)-3

KW - Nuclear factor (NF)κB

UR - http://www.scopus.com/inward/record.url?scp=33646795341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646795341&partnerID=8YFLogxK

U2 - 10.2217/14796694.2.1.91

DO - 10.2217/14796694.2.1.91

M3 - Article

VL - 2

SP - 91

EP - 100

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 1

ER -